• Explore /
  • Poster
  • / First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.

First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.

Abstract Video & Slides Poster

Authors

Nong Xu

Nong Xu

The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Nong Xu , Yulong Zheng , Haijun Zhong , Fuyou Zhao , Huan Zhou , Chenyu Mao , Wangxia Lv , Meiqin Yuan , Jiong Qian , Haiping Jiang , Zishu Wang , Cheng Xiao , Ting Liu , Wei Liu , Baiyong Li , Yu Xia

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Cancer Angiogenesis and Metastases

Clinical Trial Registration Number

NCT04547205

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3021)

DOI

10.1200/JCO.2022.40.16_suppl.3021

Abstract #

3021

Poster Bd #

13

Abstract Disclosures

Similar Posters

First Author: Jessica Dreger McDermott

First Author: Xiao-Li Wei

First Author: Vivek Subbiah

First Author: Ying Cheng